A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
A legfontosabb adatok
- Hol
- Boston, Cutler Bay, Fremont, Northridge, Portsmouth, San Antonio, Santa Clarita, South Jordan és Troy (Egyesült Államok)Mind a 9 helyszín megnézése
- Fázis
- 2. fázis
Neked szólhat?
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 60 év között vagy?
Forrás: NCT07533006: ki vehet részt
Helyszínek itt: Egyesült Államok
- Brigham and Women's HospitalBoston, Egyesült ÁllamokContact: Arash Mostaghimi (principal investigator)Résztvevőt keres
- Health Clinical Research, LLCCutler Bay, Egyesült ÁllamokContact: Soroush Aghigh (principal investigator)Résztvevőt keres
- Center For Dermatology Clinical Research, Inc.Fremont, Egyesült ÁllamokContact: Sunil Dhawan (principal investigator)Résztvevőt keres
- Northridge Clinical TrialsNorthridge, Egyesült ÁllamokContact: Navid Ezra (principal investigator)Résztvevőt keres
- StracskinPortsmouth, Egyesült ÁllamokContact: Abel Jarell (principal investigator)Résztvevőt keres
- Texas Dermatology and Laser Specialists - San Antonio - South New Braunfels AvenueSan Antonio, Egyesült ÁllamokContact: John Browning (principal investigator)Résztvevőt keres
- Cura Clinical Research - Santa Clarita - Kelly Johnson ParkwaySanta Clarita, Egyesült ÁllamokContact: Bernard Raskin (principal investigator)Résztvevőt keres
- Jordan Valley Dermatology & Research CenterSouth Jordan, Egyesült ÁllamokContact: Douglass Forsha (principal investigator)Résztvevőt keres
- Revival Research Institute, LLCTroy, Egyesült ÁllamokContact: Ali Moiin (principal investigator)Résztvevőt keres
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakA vizsgálat adatai
- Ki végzi
- Eli Lilly and Company
- Azonosító
- NCT07533006EU 2025-524727-41-00
- A regiszteradat frissítve
- 2026. november 4.
- Eredeti leírás
The purpose of this study is to evaluate how well LY4005130 works in participants with severe alopecia areata (hair loss) when compared with placebo, and how well it's tolerated and what side effects may occur. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.A teljes eredeti leírásKevesebb
A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Proof of Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants With Severe Alopecia Areata
The purpose of this study is to evaluate how well LY4005130 works in participants with severe alopecia areata (hair loss) when compared with placebo, and how well it's tolerated and what side effects may occur. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.
The study drug will be administered intravenously (IV) (into a vein in the arm).
The study will last approximately 48 weeks, including screening.
Bevonási feltételek: Have severe Alopecia Areata (AA) that meets all of the following criteria:; Hair loss encompassing ≥50% and ≤90% of the scalp, as measured by Severity of Alopecia Tool (SALT) score; The duration of the current episode of severe AA is at least 6 months and does not exceed 4 years; No significant spontaneous hair regrowth in the investigator's opinion for at least 6 months; Agree not to use any AA treatments during the study.
Kizáró feltételek: Participants who, in the opinion of the investigator, are currently experiencing or have a history of unstable concomitant disease that requires frequent hospitalizations, and/or frequent use of systemic immunosuppressants that may interfere with participation in the study; Have had any major surgery within 8 weeks prior to screening or will require major surgery during the study; Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness; Primarily "diffuse" type of AA (characterized by diffuse hair shedding); Are currently experiencing other forms of alopecia.